SAN DIEGO, April 16, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced today at the 2008 Annual Meeting of AACR in San Diego, CA, the development of new cytokine-antibody conjugates using the Company’s and its subsidiary, IBC Pharmaceuticals, Inc.'s proprietary Dock-and-Lock method (DNL).
